Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 40, Issue 9

Issues

Reduction of the Rate of False-Positive Cultures of Mycobacterium tuberculosis in a Laboratory with a High Culture Positivity Rate

Nora M. Carroll / Madalene Richardson / Erica Engelke / Marianna de Kock / Carl Lombard / Paul D. van Helden
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2002.157

Abstract

Our laboratory, engaged in a prospective study of adult pulmonary tuberculosis, processed on average 1186 sputum samples per year for the detection of Mycobacterium tuberculosis (M. tuberculosis). Approximately 55% of all sputum samples were culture-positive. The study protocol required that all patients had their M. tuberculosis isolates DNA fingerprinted at diagnosis, and at subsequent time points if the patients either failed treatment or presented again with tuberculosis. Over a 22-month period, there were 14 apparent treatment failures from 109 patients who had completed 6 months of therapy. Only two of these were true treatment failures, while the other 12 had DNA fingerprints that were different from those obtained at diagnosis. It was concluded that these 12 cultures represented episodes of laboratory cross-contamination. Retrospective DNA fingerprinting of patient isolates was done so that each patient had at least two independent isolates fingerprinted. This survey revealed that 7.3% of DNA fingerprints were discordant. False-positive cultures with discordant DNA fingerprints generally arose late in chemotherapy and the isolates were usually co-processed with other strongly smear-positive sputum samples. Simple modifications of laboratory procedures were made, and over a following 10.5-month period the false-positive rate was reduced to 2.1%. These modifications did not increase the workload or the cost of processing samples and can thus be used successfully by any laboratory, and particularly by those in resource-poor settings.

About the article

Published Online: 2005-06-01

Published in Print: 2002-09-24


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 40, Issue 9, Pages 888–892, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2002.157.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Aleksandra Barac, Hannah Karimzadeh-Esfahani, Mahya Pourostadi, Mohammad Taghi Rahimi, Ehsan Ahmadpour, Jalil Rashedi, Behroz Mahdavipoor, Hossein Samadi Kafil, Adel Spotin, Kalkidan Hassen Abate, Alexander G. Mathioudakis, and Mohammad Asgharzadeh
Lung, 2019
[2]
Sanne C van Kampen, Richard M Anthony, and Paul R Klatser
BMC Infectious Diseases, 2010, Volume 10, Number 1
[3]
F. M. Marx, R. Dunbar, D. A. Enarson, B. G. Williams, R. M. Warren, G. D. van der Spuy, P. D. van Helden, and N. Beyers
Clinical Infectious Diseases, 2014, Volume 58, Number 12, Page 1676
[4]
Meng-Rui Lee, Kuei-Pin Chung, Wei-Ting Chen, Yu-Tsung Huang, Li-Na Lee, Chong-Jen Yu, Lee-Jene Teng, Po-Ren Hsueh, Pan-Chyr Yang, and Kwen-Tay Luh
Diagnostic Microbiology and Infectious Disease, 2012, Volume 73, Number 4, Page 343
[5]
Saskia den Boon, Schalk W.P. van Lill, Martien W. Borgdorff, Donald A. Enarson, Suzanne Verver, Eric D. Bateman, Elvis Irusen, Carl J. Lombard, Neil W. White, Christine de Villiers, and Nulda Beyers
Emerging Infectious Diseases, 2007, Volume 13, Number 8, Page 1189
[6]
N.M. Carroll, P. Uys, A. Hesseling, K. Lawrence, C. Pheiffer, F. Salker, K. Duncan, N. Beyers, and P.D. van Helden
Tuberculosis, 2008, Volume 88, Number 6, Page 624
[7]
David A.J. Moore, Luz Caviedes, Robert H. Gilman, Jorge Coronel, Fanny Arenas, Doris LaChira, Cayo Salazar, Juan Carlos Saravia, Richard A. Oberhelman, Maria-Graciela Hollm-Delgado, A. Roderick Escombe, Carlton A.W. Evans, and Jon S. Friedland
Diagnostic Microbiology and Infectious Disease, 2006, Volume 56, Number 1, Page 35
[8]
George J. Alangaden, William J. Brown, and P.H. Chandrasekar
Infectious Diseases in Clinical Practice, 2004, Volume 12, Number 6, Page 328
[9]
Freda Maree, Anneke C. Hesseling, H Simon Schaaf, Ben J. Marais, Nulda Beyers, Paul van Helden, Robin M. Warren, and Johan F. Schoeman
The Pediatric Infectious Disease Journal, 2007, Volume 26, Number 1, Page 13
[10]
H. Veenstra, R. Baumann, N. M. Carroll, P. T. Lukey, M. Kidd, N. Beyers, C. T. Bolliger, P. D. van Helden, and G. Walzl
Clinical and Experimental Immunology, 2006, Volume 145, Number 2, Page 252

Comments (0)

Please log in or register to comment.
Log in